Embecta Corp. is facing a securities class action lawsuit on behalf of investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit alleges that the company made misleading assurances about the stability and resilience of its pen needle business, which historically comprised over 70% of total revenues, while knowing or recklessly disregarding weaknesses in the pen needle market that were likely to significantly disrupt its annual guidance and second-quarter results. On May 5, 2026, Embecta reported second-quarter adjusted earnings per share of $0.27, a roughly 61% sequential and year-over-year decline, and slashed its full-year 2026 adjusted EPS guidance to $1.55 to $1.75, down about 43% at the midpoint, while also reducing its dividend by 93% to just $0.01. The stock price tumbled following the report, and shareholder rights firm Hagens Berman has opened an investigation into potential violations of federal securities laws. The lead plaintiff deadline is August 17, 2026.
Embecta CorpLawsuit alleges misleading statements about pen needle revenue; company reported sharp earnings decline and slashed guidance and dividend.